Deregulated miRNAs and their targeted genes are associated with the hallmarks of cancer, including melanoma, acting as tumor suppressors or oncogenes [19,20,21], and they may be potential therapeutic targets in melanomas, including those with BRAF mutations [22], by strengthening sensitivity to the standard therapies and immune checkpoint inhibitors [9]. This evidence concerns the gene BRAF and melanoma.